Drugs / Engineering Tumor Infiltrating Lymphocytes
Engineering Tumor Infiltrating Lymphocytes
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06375187 | May 2024 → Nov 2026 expected | digestive system cancer, female breast carcinoma, female reproductive organ cancer, lung cancer | Shanghai Juncell Therapeutics | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Engineering Tumor Infiltrating Lymphocytes | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06375187 ↗ |
| Modality | Cell therapy | “engineered Tumor Infiltrating Lymphocytes (TIL)” NCT06375187 ↗ |